Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
N Engl J Med
    January 2024
  1. SHORE ND, Tarazi J, Freedland SJ
    Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
    N Engl J Med. 2024;390:90-91.
    >> Share

  2. POLLAK M
    Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2024;390:90.
    >> Share

    October 2023
  3. APARICIO A
    Biochemical Recurrence in Prostate Cancer - Tilting the Scale.
    N Engl J Med. 2023;389:1522-1523.
    >> Share

  4. FREEDLAND SJ, de Almeida Luz M, De Giorgi U, Gleave M, et al
    Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2023;389:1453-1465.
    >> Share

  5. NADAMUNI M, D'Amico AV, Donovan JL, Hamdy FC, et al
    Decision Making in Prostate Cancer.
    N Engl J Med. 2023;389:1335-1338.
    >> Share

    July 2023
  6. PINSKY PF, Parnes H
    Screening for Prostate Cancer. Reply.
    N Engl J Med. 2023;389:94.
    >> Share

  7. PRESTI J JR, Alexeeff S, Avins AL
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:93-94.
    >> Share

  8. INAMURA K
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:93.
    >> Share

  9. HOOVER J, Butterfass C, Ponder A
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:92-93.
    >> Share

  10. HAMDY FC, Donovan JL
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.
    N Engl J Med. 2023;389:92.
    >> Share

  11. DAVIS MJ, Stephens A, Abdollah F
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.
    N Engl J Med. 2023;389:90-92.
    >> Share

    June 2023

  12. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023;388:2208.
    >> Share

    April 2023

  13. Waiting on Prostate Cancer.
    N Engl J Med. 2023;388:e54.
    >> Share

  14. PINSKY PF, Parnes H
    Screening for Prostate Cancer.
    N Engl J Med. 2023;388:1405-1414.
    >> Share

    March 2023
  15. SARTOR O
    Localized Prostate Cancer - Then and Now.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMe2300807.
    >> Share

  16. HAMDY FC, Donovan JL, Lane JA, Metcalfe C, et al
    Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMoa2214122.
    >> Share

    February 2023
  17. FIZAZI K, Piulats JM, Reaume MN, Ostler P, et al
    Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
    >> Share

  18. GAGLIANO-JUCA T, Hirsch MS, McGregor BA, Basaria S, et al
    Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
    N Engl J Med. 2023;388:660-662.
    >> Share

    December 2022
  19. GULATI R
    Reducing Prostate Cancer Overdiagnosis.
    N Engl J Med. 2022;387:2187-2188.
    >> Share

  20. HUGOSSON J, Mansson M, Wallstrom J, Axcrona U, et al
    Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    N Engl J Med. 2022;387:2126-2137.
    >> Share

    September 2022

  21. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2022;387:860.
    >> Share

    June 2022
  22. SMITH MR
    Darolutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2022;386:2345.
    >> Share

  23. BOWLING GC, Dimitrakoff JD
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    >> Share

  24. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    >> Share

    February 2022
  25. SMITH MR, Hussain M, Saad F, Fizazi K, et al
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    N Engl J Med. 2022 Feb 17. doi: 10.1056/NEJMoa2119115.
    >> Share

    December 2021
  26. SARTOR O, Morris MJ, Kraus BJ
    Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    N Engl J Med. 2021;385:2495-2496.
    >> Share

  27. DALLA VOLTA A, Grisanti S, Berruti A
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2495.
    >> Share

  28. KASHIHARA T, Kashihara K
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494-2495.
    >> Share

  29. HINDIE E
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494.
    >> Share

    November 2021
  30. EKLUND M, Discacciati A, Nordstrom T
    MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
    N Engl J Med. 2021;385:2110-2111.
    >> Share

  31. YOSHIDA S, Fujii Y
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2110.
    >> Share

  32. AL HUSSEIN AL AWAMLH B, Spratt DE, Shoag JE
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2109-2110.
    >> Share

    July 2021
  33. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    >> Share

    June 2021
  34. SARTOR O, de Bono J, Chi KN, Fizazi K, et al
    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016